용한점집 금휘궁 갤러리

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Abstract

Nitroglycerin (glyceryl trinitrate, GTN), a simple nitrate ester of glycerol, represents one of the most remarkable therapeutic transformations in medical history. Originally synthesized in 1847 by Ascanio Sobrero as a powerful explosive, its profound vasodilatory effects were later discovered, leading to its establishment as a first-line treatment for angina pectoris. This article reviews the chemistry, pharmacology, mechanisms of action, clinical applications, and the phenomenon of nitrate tolerance associated with nitroglycerin. We explore its journey from a compound of industrial and military significance to an indispensable cardiovascular agent, highlighting the intricate biochemistry of nitric oxide (NO) signaling that underpins its therapeutic efficacy.

Introduction

Nitroglycerin (C₃H₅N₃O₉) is an organic nitrate with a storied dual identity. Its explosive properties, harnessed by Alfred Nobel in dynamite, contrast sharply with its life-saving role in medicine. The serendipitous observation by workers in dynamite factories of relief from chest pain and weekend headaches (Monday disease) paved the way for William Murrell's seminal 1879 publication advocating its use for angina. Today, it remains a cornerstone in the management of ischemic heart disease, acting as a prodrug that releases nitric oxide, a key endogenous signaling molecule.

Chemistry and Pharmacokinetics

Chemically, nitroglycerin is the tri-nitrate ester of glycerol. Its instability and sensitivity to shock, heat, and friction stem from the presence of multiple nitro groups in a molecular configuration that readily undergoes exothermic decomposition. Therapeutically, it is administered via routes that bypass extensive first-pass hepatic metabolism, which rapidly denitrates GTN to inactive metabolites. Sublingual tablets or sprays provide rapid onset (1-3 minutes) for acute angina relief, with a short duration of action (10-30 minutes). Transdermal patches, ointments, and intravenous formulations allow for sustained delivery in prophylactic or hospital settings. Its volume of distribution is large, and clearance is primarily via enzymatic degradation in the liver and vascular tissue.

Mechanism of Action: The Nitric Oxide Pathway

The therapeutic action of nitroglycerin is mediated through its bioconversion to nitric oxide (NO). This process is complex and requires mitochondrial aldehyde dehydrogenase (mtALDH or ALDH2) in vascular smooth muscle cells. Specifically, mtALDH catalyzes the reduction of GTN, releasing nitrite and ultimately bioactive NO. This enzymatic step explains the phenomenon of nitrate tolerance, as prolonged exposure depletes or inactivates mtALDH.

The released NO then diffuses into vascular smooth muscle cells and activates soluble guanylyl cyclase (sGC). This enzyme catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Elevated intracellular cGMP activates protein kinase G (PKG), leading to a cascade that results in the dephosphorylation of myosin light chains and smooth muscle relaxation. The primary hemodynamic effects are:

• 
  
• Venodilation: Predominant at low doses, leading to reduced venous return (preload) and ventricular wall tension, thereby decreasing myocardial oxygen demand.
  
• Arteriolar Dilation: At higher doses, reduces systemic vascular resistance and arterial pressure (afterload), further lowering cardiac workload.
  
• Coronary Vasodilation: Dilates epicardial coronary arteries and collateral vessels, improving blood flow to ischemic regions of the myocardium.
  

This multifaceted reduction in myocardial oxygen demand, coupled with improved supply, is the basis for its anti-anginal effect.

Clinical Applications

Nitroglycerin's primary indication is the treatment and prevention of angina pectoris due to coronary artery disease.

1. 
   
2. Acute Angina Relief: Sublingual formulation is the standard for immediate relief of an anginal attack.
   
3. Prophylaxis: Used prior to activities known to induce angina (e.g., exercise, sexual activity).
   
4. Unstable Angina & Acute Coronary Syndromes: Intravenous GTN is used to control ongoing ischemia and manage hypertension or pulmonary congestion in a monitored setting.
   
5. Congestive Heart Failure: Used as a vasodilator to reduce preload and afterload in acute decompensated heart failure.
   
6. Hypertensive Emergencies: Intravenous infusion can provide rapid, titratable blood pressure control.
   
7. Anal Sphincter Relaxation: Topical formulations are sometimes used in chronic anal fissures.
   

Contraindications include hypersensitivity, severe anemia, concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil), which potentiate hypotension, and hypertrophic obstructive cardiomyopathy.

Nitrate Tolerance and Cross-Tolerance

A significant limitation of continuous nitroglycerin therapy is the rapid development of tolerance, where the hemodynamic and anti-ischemic effects diminish within 24 hours. The mechanisms are multifactorial and include:

• 
  
• Impaired Bioconversion: Depletion of sulfhydryl groups necessary for enzymatic activity and inactivation of mtALDH.
  
• Neurohormonal Counter-regulation: Activation of the renin-angiotensin-aldosterone system and sympathetic nervous system, leading to vasoconstriction and fluid retention.
  
• Oxidative Stress: Increased production of superoxide anions which scavenge NO, reducing its bioavailability.
  

To prevent tolerance, a daily nitrate-free interval (e.g., 10-12 hours for transdermal patches) is standard practice. This allows for restoration of enzymatic activity and sensitivity. Cross-tolerance can occur with other organic nitrates (e.g., isosorbide dinitrate).

Adverse Effects

Most adverse effects are extensions of its vasodilatory pharmacology and are dose-dependent. Common effects include headache (due to cerebral vasodilation), flushing, Tamiflu 75 mg al mejor precio €6.06 : Oseltamivir; https://buentrago.es, dizziness, and postural hypotension. Reflex tachycardia may occur as a compensatory response to hypotension. Methemoglobinemia, though rare, can occur with high-dose intravenous therapy, as nitrates can oxidize hemoglobin iron from ferrous (Fe²⁺) to ferric (Fe³⁺) state.

Conclusion and Future Perspectives

Nitroglycerin remains an essential, fast-acting therapeutic agent for angina pectoris over 140 years after its introduction. Its story exemplifies translational science, where understanding a compound's biological effects unlocked a revolutionary treatment. The discovery that its mechanism involves the endogenous NO pathway further cemented its scientific importance, contributing to the 1998 Nobel Prize in Physiology or Medicine for the role of NO as a signaling molecule.

Current research focuses on overcoming nitrate tolerance through novel delivery systems, co-administration with antioxidants or agents that replenish sulfhydryl groups, and the development of NO donors that bypass the ALDH2 pathway. Furthermore, the genetic polymorphism in the ALDH2 gene, prevalent in East Asian populations, which reduces GTN efficacy, highlights the growing importance of pharmacogenomics in personalized cardiovascular therapy. Despite its age, nitroglycerin continues to be a vital tool, and the study of its actions continues to inform our understanding of vascular biology and therapeutics.